Reducing therapeutic inertia in type 2 diabetes

被引:0
作者
Stroud, Mark L. [1 ]
Malik, Asif N. [1 ]
Ahmad, Shahid [1 ]
Ahmed, Saqib [1 ]
Kadhem, Leena Abdulla [1 ]
机构
[1] Primary Hlth Care Corp, Mesaimeer Hlth Ctr, Dept Family Med, Doha, Qatar
关键词
CLINICAL INERTIA; TIME; PEOPLE;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Therapeutic inertia describes a failure to establish appropriate treatment targets and escalate treatment to achieve those targets. This inertia can be measured, and evidence of this inertia is present in approximately one-third of diabetes management consultations. This inertia describes a failure in the system to produce change, rather than assigning fault to the physician or patient. Objective This article discusses the importance of reducing therapeutic inertia in type 2 diabetes and focusing on reducing overall cardiovascular risk. Discussion This article discusses approaches to reducing treatment inertia in type 2 diabetes (ie identify the problem, get permission, set goals, measure progress and alter treatment to reach those goals). The treat-to-target methodology, the STABLE (Smoking cessation, Target organ involvement, HbA1c, Blood pressure, Lipid profile, Energy balance) acronym and practical approaches are described.
引用
收藏
页码:665 / 670
页数:6
相关论文
共 27 条
  • [1] American Diabetes Association, 2022, Clin Diabetes, V41, P4, DOI 10.2337/cd23-as01
  • [2] [Anonymous], 2022, Type 2 diabetes in adults: choosing medicines [Internet]
  • [3] [Anonymous], 2019, National health survey: Health literacy, 2018
  • [4] Australian Institute of Health and Welfare, 2023, Diabetes: Australian Facts
  • [5] Why are clinical practice guidelines not followed?
    Barth, Julian H.
    Misra, Shivani
    Aakre, Kristin Moberg
    Langlois, Michel R.
    Watine, Joseph
    Twomey, Patrick J.
    Oosterhuis, Wytze P.
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2016, 54 (07) : 1133 - 1139
  • [6] The Importance of Considering Clinical Inertia and Implementation Science When Addressing Medication Adherence
    Bosworth, Hayden B.
    [J]. JAMA NETWORK OPEN, 2020, 3 (10)
  • [7] Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes
    Carls, Ginger S.
    Tuttle, Edward
    Tan, Ruo-Ding
    Huynh, Johnny
    Yee, John
    Edelman, Steven V.
    Polonsky, William H.
    [J]. DIABETES CARE, 2017, 40 (11) : 1469 - 1478
  • [8] Deed G, 2012, AUST FAM PHYSICIAN, V41, P681
  • [9] Guzman Susan J, 2020, Diabetes Spectr, V33, P38, DOI 10.2337/ds19-0024
  • [10] HART JT, 1992, BRIT J GEN PRACT, V42, P116